Adicet Bio, Inc. (Market cap: $75.8M), a biopharmaceutical company currently rated 'FAIR' by InvestingPro's Financial Health scoring system, has announced updates on the enrollment of its clinical ...

Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...

Adicet Bio (ACET) announced the FDA has granted fast track designation to ADI-001 for the potential treatment of adult patients with refractory ...

The Lupus Foundation of America is holding an informational and support group at 6:30 p.m. Feb. 10 at the Lima Public Library, 650 W. Market St. in Lima. No registration is required. For more ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

Lupus is a chronic autoimmune disease that disproportionately affects racial and ethnically minoritized populations, ...

The odds of developing systemic lupus erythematosus or systemic sclerosis appear to significantly increase with the use of ...

The following is a summary of “Nomogram for predicting proliferative lupus nephritis in patients with low-level proteinuria,” ...

The following is a summary of “Distinct genetic risk loci between biopsy-proven renal and non-renal lupus: a 10-year ...

Patients with Klinefelter and triple X syndromes show an increased prevalence of SLE and Sjögren disease, likely due to the ...

Individuals with cutaneous lupus erythematosus have an increased ASCVD risk when compared with those without cutaneous lupus erythematosus.

EULAR/ACR SLE classification criteria were not linked to mortality or hospitalization, a developed ominosity model adequately predicted mortality.